<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030">Here we provide information that justifies a clinical trial of hydroxychloroquine [
 <xref rid="bb0005" ref-type="bibr">1</xref>] as a post-exposure drug together with the background needed to safely and properly design such a clinical trial, taking into consideration the PK/PD of hydroxychloroquine, its action against virus including 
 <italic>Coronaviridae</italic>, its potential toxicity in humans and the impact of repurposing for patients with inflammatory diseases.
</p>
